Results 61 to 70 of about 7,978,447 (307)

Assessment of Visit‐to‐Visit Blood Pressure Variability in Adults With Optimal Blood Pressure: A New Player in the Evaluation of Residual Cardiovascular Risk?

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background There is a paucity of evidence regarding the association between visit‐to‐visit blood pressure variability and residual cardiovascular risk.
Menghui Liu, Xiaohong Chen, Shaozhao Zhang, Junfan Lin, Lichun Wang, Xinxue Liao, Xiaodong Zhuang   +6 more
doaj   +1 more source

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation

Frontiers in Cardiovascular Medicine, 2023
Atrial fibrillation is a complex and multifactorial disease. Although prophylactic anticoagulation has great benefits in avoiding comorbidities, adverse cardiovascular events still occur and thus in recent decades, many resources have been invested in the identification of useful markers in the prevention of the risk of MACE in these patients. As such,
Ascensión M. de los Reyes-García, Laura Zapata-Martínez, Sonia Águila, María L. Lozano, Constantino Martínez, Rocío González-Conejero   +5 more
openaire   +3 more sources

Adverse events based on serum bilirubin levels.

, 2013
Values are number (%).MI: myocardial infarction; MACE: major adverse cardiovascular event.
Shao-Sung Huang (312696), Jaw-Wen Chen (174650), Po-Hsun Huang (183737), Tao-Cheng Wu (183746), Shing-Jong Lin (174700)   +4 more
core   +1 more source

Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)

, 2023
The role of soluble suppression of tumorigenicity (sST2) as a biomarker in predicting clinical outcomes in patients with cardiovascular diseases (CVD) has not been fully elucidated.
Dongqing Chen, Stuart Sugito, Amanda J. Croft, Aaron L. Sverdlov, Bahador Assadi-Khansari, Glykeria Stavropoulou, Rossana Untaru, Nicholas J. Collins, Conagh Kelly, Doan T. M. Ngo   +9 more
core   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events [PDF]

Journal of Thrombosis and Thrombolysis, 2017
Systemic lupus erythematosus (SLE) is a significant risk factor for cardiovascular disease. The relationship between SLE and perioperative cardiovascular risks following non-cardiac surgery is uncertain. We investigated associations between a diagnosis of SLE and outcomes following major non-cardiac surgery in a large national database from the United ...
Nathaniel R, Smilowitz, Gregory, Katz, Jill P, Buyon, Robert M, Clancy, Jeffrey S, Berger   +4 more
openaire   +2 more sources

Multivariate Cox analysis for major adverse cardiovascular events.

, 2015
Multivariate Cox analysis for major adverse cardiovascular events.
Jiaojiao Xu (813939), Dongyu Xia (813940), Yu Xiang (261980), Lan Mi (813938), Na Zhao (112953), Zhongwei Liu (723226), Yong Zhang (5893), Zuyi Yuan (143452), Gongchang Guan (813941), Shuo Pan (583102), Xiaojun Liu (58952), Junkui Wang (813942)   +11 more
core   +1 more source

Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son, Inyoung Hwang, Sang Won Lee, Yun Kim   +3 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Obesity and atrial fibrillation (AF) frequently coexist and independently increase mortality. We sought to assess the association between obesity and adverse events in patients receiving oral anticoagulants for AF.
Vicente Bertomeu‐Gonzalez, José Moreno‐Arribas, María Asunción Esteve‐Pastor, Inmaculada Roldán‐Rabadán, Javier Muñiz, Paula Raña‐Míguez, Martín Ruiz‐Ortiz, Ángel Cequier, Vicente Bertomeu‐Martínez, Lina Badimón, Manuel Anguita, Gregory Y. H. Lip, Francisco Marín   +12 more
doaj   +1 more source